KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Common Equity data on record, last reported at $31.0 billion in Q3 2025.

  • For Q3 2025, Common Equity rose 5.56% year-over-year to $31.0 billion; the TTM value through Sep 2025 reached $31.0 billion, up 5.56%, while the annual FY2024 figure was $29.4 billion, 13.02% up from the prior year.
  • Common Equity reached $31.0 billion in Q3 2025 per REGN's latest filing, up from $29.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $31.0 billion in Q3 2025 and bottomed at $12.0 billion in Q1 2021.
  • Average Common Equity over 5 years is $23.9 billion, with a median of $24.0 billion recorded in 2023.
  • The widest YoY moves for Common Equity: up 67.02% in 2021, down 1.29% in 2021.
  • A 5-year view of Common Equity shows it stood at $17.3 billion in 2021, then surged by 31.32% to $22.7 billion in 2022, then increased by 14.6% to $26.0 billion in 2023, then grew by 13.02% to $29.4 billion in 2024, then rose by 5.47% to $31.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $31.0 billion in Q3 2025, $29.9 billion in Q2 2025, and $29.4 billion in Q1 2025.